Labcorp Holdings Inc. (LON:0JSY)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 15.43B +7.6% |
| Revenue (ttm) | 10.71B +7.3% |
| Net Income | 713.00M +28.8% |
| EPS | 8.55 +30.2% |
| Shares Out | n/a |
| PE Ratio | 21.64 |
| Forward PE | 13.86 |
| Dividend | 2.15 (0.84%) |
| Ex-Dividend Date | Feb 27, 2026 |
| Volume | 3 |
| Average Volume | 259 |
| Open | 253.47 |
| Previous Close | 256.79 |
| Day's Range | 252.86 - 257.93 |
| 52-Week Range | 238.93 - 297.30 |
| Beta | 0.88 |
| RSI | 43.43 |
| Earnings Date | Apr 30, 2026 |
About Labcorp Holdings
Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target speci... [Read more]
Financial Performance
In 2025, Labcorp Holdings's revenue was $13.95 billion, an increase of 7.25% compared to the previous year's $13.01 billion. Earnings were $876.50 million, an increase of 17.49%.
Financial numbers in USD Financial StatementsNews
Labcorp, Epic expand collaboration
Labcorp (LH) announced an expanded collaboration with Epic, the nation’s leading electronic health record supporting hospitals and health systems. Through the collaboration, Labcorp’s full test menu w...
Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems
Labcorp's full test menu will be available through Epic's Aura platform Integration builds on the successful deployment of Invitae genetic testing and accelerates access to the latest genetic and spec...
Labcorp price target raised to $334 from $332 at Baird
Baird analyst Eric Coldwell raised the firm’s price target on Labcorp (LH) to $334 from $332 and keeps an Outperform rating on the shares. The firm updated its model following…
Labcorp reports Q1 adjusted EPS $4.25, consensus $4.12
Reports Q1 revenue $3.54B, consensus $3.51B. “Labcorp (LH) delivered another quarter of strong results, with robust growth and double-digit Adjusted EPS growth driven by continued momentum across our ...
Labcorp raises FY26 adjusted EPS view to $17.70-$18.35 from $17.55-$18.25
Consensus $17.79. Raises FY26 revenue view to $14.65B-$14.8B from $14.61B-$14.79B, consensus $14.67B. The company said, “Labcorp (LH) is updating 2026 full year guidance to reflect its first quarter p...
Labcorp Holdings Earnings Call Transcript: Q1 2026
Q1 2026 delivered 5.8% revenue growth, 10.6% EPS growth, and margin expansion, driven by strong Diagnostics and BLS performance, specialty testing, and strategic partnerships. Guidance for 2026 was raised, with continued focus on innovation, M&A, and operational efficiency.
Labcorp raises full-year forecasts on steady diagnostics demand
Labcorp raised its full-year profit and revenue forecast on Thursday after posting quarterly results above expectations as demand for diagnostic testing remained steady.
Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 Guidance
Results from Operations for first quarter 2026 versus first quarter 2025: Revenue: $3.54 billion vs. $3.35 billion, up 5.8% Diluted EPS: $3.35 vs.
Labcorp announces availability of Agilent’s PD-L1 IHC 22C3 pharmDx
Labcorp (LH) announced the nationwide availability of Agilent Technologies’ (A) PD-L1 IHC 22C3 pharmDx, the only companion diagnostic approved by the U.S. FDA to identify patients with platinum-resist...
Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®
BURLINGTON, N.C., April 22, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of Agilent Technol...
d-wise Appoints 2x-CEO, ex-Labcorp Head of Software Solutions to Drive Next Phase of Strategy & Growth
BOSTON--(BUSINESS WIRE)--d-wise (an Instem company), a leader in statistical computing infrastructure and clinical trial transparency, today announced the appointment of Christine Oliver as its Presid...
Labcorp announces launch of Labcorp Fentanyl Urine Visual Test
Labcorp (LH) announced the launch of the Labcorp Fentanyl Urine Visual Test, the first U.S. FDA-cleared rapid fentanyl test of its kind manufactured in the United States. The test delivers…
Labcorp Launches FDA-Cleared Fentanyl Test Delivering Results in 10 Minutes
First FDA-cleared rapid fentanyl test of its kind made in the United States designed to help emergency department and hospital teams act quickly when every second counts Fentanyl Urine Visual Test is ...
Labcorp launches new AI-powered real-world data platform with AWS
Labcorp (LH) announced a new AI-powered real-world data platform, designed to help researchers and biopharmaceutical companies analyze Alzheimer’s disease-related data faster. Developed with Amazon We...
Labcorp Introduces AI-Powered Real-World Data Platform with AWS and Datavant to Accelerate Alzheimer's Research
Platform leverages agentic AI and diverse healthcare datasets to transform and speed drug development BURLINGTON, N.C., April 14, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative...
Children's Hospital of Philadelphia and Labcorp Announce a Collaboration to Accelerate Access to Advanced Pediatric Diagnostics Nationwide
Collaboration aims to speed the discovery, development and national availability of specialized pediatric diagnostics BURLINGTON, N.C. and PHILADELPHIA, April 13, 2026 /PRNewswire/ -- Labcorp (NYSE: L...
Labcorp Declares Quarterly Dividend
BURLINGTON, N.C., April 9, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has d...
Labcorp price target raised to $300 from $280 at Evercore ISI
Evercore ISI raised the firm’s price target on Labcorp (LH) to $300 from $280 and keeps an Outperform rating on the shares. The firm made several price target adjustments and…
Labcorp to Announce First Quarter Financial Results on April 30, 2026
BURLINGTON, N.C., March 31, 2026 /PRNewswire/ -- Labcorp Holdings Inc.
Labcorp, Illumina expand collaboration to broaden access to oncology testing
Illumina (ILMN) and Labcorp (LH) announced an expanded collaboration to advance precision oncology through applications of next-generation sequencing solutions across the healthcare ecosystem. Project...
Illumina and Labcorp expand collaboration to broaden access to precision oncology testing
SAN DIEGO, March 18, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collabo...
Labcorp price target raised to $300 from $270 at Piper Sandler
Piper Sandler analyst David Westenberg raised the firm’s price target on Labcorp (LH) to $300 from $270 following quarterly results. The firm keeps a Neutral rating on the shares. Published…
Labcorp collaborates with PathAI to deploy FDA-cleared pathology platform
Labcorp (LH) announced an expanded collaboration with PathAI to deploy AISight Dx1, an FDA-cleared digital pathology platform, across its national network of anatomic pathology labs and hospital colla...
Labcorp Expands Collaboration with PathAI to Deploy FDA-Cleared Digital Pathology Platform Nationwide
AISight® Dx will support fully digital workflows and AI-enabled insights across Labcorp's network of anatomic pathology labs and hospital collaborations to improve efficiency, collaboration and patien...
Labcorp price target raised to $326 from $313 at Baird
Baird raised the firm’s price target on Labcorp (LH) to $326 from $313 and keeps an Outperform rating on the shares. The firm updated is model following Q4 results. Published…